Cellectis Reports Financial Results for the First Quarter 2025

Core Insights - Cellectis reported financial results for Q1 2025, highlighting progress in clinical studies and partnerships, particularly with AstraZeneca [1][2][9] Financial Results - As of March 31, 2025, Cellectis had a cash position of $246 million, down from $264 million at the end of 2024, providing a runway into H2 2027 [10][11] - Consolidated revenues and other income for Q1 2025 were $12.0 million, an increase from $6.5 million in Q1 2024, primarily due to a $5.9 million increase in revenue recognized under the AstraZeneca joint research collaboration agreement [13][14] - R&D expenses for Q1 2025 were $21.9 million, slightly down from $22.3 million in Q1 2024, while SG&A expenses decreased to $4.7 million from $5.1 million [15][16] - The consolidated net loss attributable to shareholders was $18.1 million for Q1 2025, compared to a net income of $5.6 million in Q1 2024 [19][20] Pipeline Highlights - Cellectis is advancing its clinical programs, including the BALLI-01 study for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia, with results expected in Q3 2025 [3][6][7] - The NATHALI-01 study for eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma is ongoing, with readout expected in late 2025 [4][7] Research and Development - Cellectis presented research data on TALEN®-mediated non-viral transgene insertion and TALE base editing at the ASGCT annual meeting, showcasing advancements in gene editing technologies [5][8] - The company is focusing on the development of its pipeline, including manufacturing and clinical trial expenses for UCART22 and UCART20x22 [12] Partnerships - Ongoing R&D activities under the AstraZeneca partnership include three programs: one allogeneic CAR T for hematological malignancies, one for solid tumors, and one in vivo gene therapy for a genetic disorder [9][6]